01—Abstract
Summary
Summary of the 10-K filed December 28, 2001. Cited figures are marked; the original filing is the authoritative source.
Gartner, Inc. reported fiscal 2001 (year ended September 30, 2001) total revenues of $952.0 milliona, up 11% from $854.6 million in fiscal 2000, but the company swung to a net loss of $66.2 million, or $(0.77) per diluted share, versus net income of $25.5 million in fiscal 2000.
The loss was driven primarily by a $66.4 millionb pre-tax loss ($39.9 million after tax) on the sale of its TechRepublic subsidiary, which is reported as a discontinued operation, along with $46.6 million of other charges (including a workforce reduction affecting 383 positions) and $26.8 million of net losses from minority-owned investments. Income from continuing operations was essentially break-even at $(0.2) million. Operating income fell 49% to $42.5 million, and operating margin was 4% versus 10% in the prior year; excluding other charges, operating income was 9.4% of revenues.
Segment results were mixed. Research revenue grew 5% to $535.1 millionc and remains about 56% of revenues, with research contract value declining 7% to approximately $556.0 million. Consulting revenue rose 27% to $265.5 million, and Events revenue rose 22% to $132.7 million, while consulting gross contribution margin fell to 33% from 36%.
Stockholders' equity turned to a deficit of $(34.5) million from $74.8 milliond a year earlier, and long-term convertible debt of $326.2 million is convertible at $7.45 per share into 43.9 million Class A shares, with a redemption option beginning April 17, 2003 and maturity on April 17, 2005. Liquidity remains adequate by management's assessment. Cash from operations was $73.5 million, cash and cash equivalents were $37.1 million at year end, and $15.0 million was drawn on a $200.0 million revolving credit facility with $123.7 million of borrowing availability.
The company repurchased stock, including 1,867,149 Class A shares from IMS Health at $9.88 per share, and authorized up to $75.0 million of additional repurchases over two years. The filing also notes that the company expects to adopt FAS 142 in its first quarter ended December 31, 2001 and has not yet estimated any transitional impairment.
02—Key points
Key Highlights
- Total revenues rose 11% to $952.0 million, with Consulting up 27% and Events up 22%, while Research grew 5% to $535.1 million.
- Net loss of $66.2 million, or $(0.77) per diluted share, compared with net income of $25.5 million in fiscal 2000, driven largely by a $66.4 million pre-tax loss on the TechRepublic sale.
- Operating income fell 49% to $42.5 million; other charges of $46.6 million included a workforce reduction eliminating 383 positions, roughly 8% of the workforce.
- Net losses from minority-owned investments of $26.8 million reflected impairment charges on early- to mid-stage Internet and IT investments.
- Stockholders' equity moved to a deficit of $(34.5) million from $74.8 million a year earlier.
- Research contract value declined 7% to approximately $556.0 million, attributed to constrained IT spending, the September 11 attacks and currency effects; excluding FX, it was down 4%.
- $326.2 million of 6% convertible notes carry a $7.45 conversion price, equal to 43.9 million Class A shares, and mature April 17, 2005; the company has a $75.0 million repurchase authorization.
03—Questions
Frequently Asked Questions
Why did Gartner swing to a net loss in fiscal 2001 despite higher revenues?
Revenues grew 11% to $952.0 million, but the net loss of $66.2 million reflected a $66.4 million pre-tax loss on the sale of the TechRepublic subsidiary (reported as a discontinued operation), $46.6 million of other charges, and $26.8 million of net losses from minority-owned investments. Costs and expenses rose to $909.5 million, and operating income fell to $42.5 million from $84.1 million.
How did the core research and consulting businesses perform?
Research revenue increased 5% to $535.1 million, with gross contribution margin of 66% versus 67% a year earlier. Consulting revenue increased 27% to $265.5 million, though its gross contribution margin declined to 33% from 36%. Events revenue increased 22% to $132.7 million. Research contract value decreased 7% to approximately $556.0 million.
What are the company's main liquidity and debt considerations?
Cash provided by operating activities was $73.5 million, and cash and cash equivalents ended the year at $37.1 million. The company had $15.0 million outstanding under a $200.0 million revolving credit facility, with $123.7 million of availability. Its $326.2 million of 6% convertible notes mature April 17, 2005, and management believes cash balances and expected cash flows are sufficient for its ordinary-course needs.
What actions did management take to reduce costs and what share repurchases were made?
The company cut its workforce by 383 positions (about 8%) in the second half of fiscal 2001, recording $24.8 million of related charges, and $6.6 million of termination benefits remained to be paid. In fiscal 2001 it purchased 1,867,149 Class A shares from IMS Health at $9.88 per share on August 29, 2001, and bought additional shares in the open market under a $75.0 million repurchase program approved July 19, 2001.
04—Continue